Results 151 to 160 of about 16,087 (221)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of dapagliflozin and eplerenone in bulk and synthetic mixture. [PDF]

BMC Chem
Tandel P, Mehta H.
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7367-7379, August 2026.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial. [PDF]

EBioMedicine
Gao R, Spiliotis I, Dou H, Hill TG, Kothegala L, Miranda C, Abiakam N, Coleman RL, White S, Adler A, Rorsman P.   +10 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7416-7429, August 2026.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Med (Lausanne)
Yin M, Tan H, Xie S, Kuang Y, Wu Q, Ma J, Guo C.   +6 more
europepmc   +1 more source

Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
As transcatheter treatment expands to younger and lower‐risk patients, aortic stenosis management is evolving from a single procedure to lifelong valve care. This review highlights the key challenges across the patient journey, from timely diagnosis and optimal intervention to durable valve performance, long‐term surveillance, and repeat intervention ...
Ottavia Cozzi, Thomas Pilgrim
wiley   +1 more source

Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement. [PDF]

Biol Direct
Li A, Ye Y, Tang J, Hu J, Shi M, Wu Y, Ji C, Zhang H.   +7 more
europepmc   +1 more source

A Case Report of Myocardial Infarction Complicated With Blood Pressure Fluctuations Caused by Pheochromocytoma

The Journal of Clinical Hypertension, Volume 28, Issue 8, August 2026.
ABSTRACT Pheochromocytoma typically presents with sustained or paroxysmal hypertension, but initial manifestation as acute non‐ST‐segment elevation myocardial infarction (NSTEMI) is rare. Peri‐procedural hemodynamic fluctuations are often dramatic, making diagnosis and management challenging.
HuiPing Li, Wei Yang, Yu Feng, You Zhang, Ganxin Yan, ChuanYu Gao   +5 more
wiley   +1 more source